Skip to main content

Bone diseases

Browse the latest news, expert commentary, and educational content on bone diseases.

01-11-2022 | Osteoporosis | News

Abaloparatide recommended for EU approval to treat osteoporosis

Click through for more details

04-10-2022 | Systemic sclerosis | News

Elevated risk for osteoporotic fractures in women with SSc

Findings from two studies suggest that more attention may need to be given to the prevention of osteoporotic fractures among women with systemic sclerosis.

21-06-2022 | Glucocorticoids | News

Low-dose glucocorticoids show no negative impact on BMD

Low glucocorticoid doses are not associated with reduced bone mineral density in people with inflammatory rheumatic and musculoskeletal diseases, observational study findings indicate.

26-05-2022 | Osteoporosis | News

UK recommendations support regular exercise for people with osteoporosis

People with osteoporosis should do regular exercise to maximize bone health and reduce fall risk, says an expert consensus statement published in the British Journal of Sports Medicine.

18-02-2022 | Osteoporosis | News

EMA recommends approval of teriparatide biosimilar for osteoporosis

Click through for further details on this announcement

11-01-2022 | Osteoporosis | News

Hip fracture risk higher during risedronate versus alendronate drug holiday

The risk for hip fracture is higher during a treatment break from risedronate than it is during a break from alendronate, study findings indicate.

24-11-2021 | Osteoporosis | News

Bisphosphonates ‘likely to be beneficial’ for most older women with osteoporosis

Findings from a meta-analysis suggest that bisphosphonate therapy for osteoporosis is most likely to benefit postmenopausal women who have a life expectancy of more than 12 months.

05-10-2021 | Rheumatoid arthritis | News

Denosumab benefits short-lived following discontinuation

Discontinuing denosumab after 1 year of treatment quickly leads to reversal of its inhibitory effect on bone turnover markers and improvements in bone mineral density among people using glucocorticoids for rheumatoid arthritis, research shows.

03-08-2021 | Rheumatoid arthritis | News

RA vertebral fracture risk increased with low-dose glucocorticoids

In patients with rheumatoid arthritis, low-dose glucocorticoids are associated with an increased risk for vertebral fracture, but not with overall or non-vertebral fractures, show findings from a UK-based retrospective cohort study.

Osteoporosis illustration

28-04-2021 | BSR 2021 | Conference coverage | News

Suboptimal prescribing of osteoporosis medications in people with polymyalgia rheumatica

Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.

05-01-2021 | Rheumatoid arthritis | News

Parallel glucocorticoid, PPI use linked to increased fracture risk in RA

Concomitant use of oral glucocorticoids and proton pump inhibitors significantly increases the risk for osteoporotic fractures in people with rheumatoid arthritis, with the combined effect greater than that for each drug class alone, research suggests.

29-10-2020 | Rheumatoid arthritis | News

Excess multimorbidity begins early in RA disease course

Multimorbidity is more common in people with versus without rheumatoid arthritis, occurs early in the disease course, and progresses more rapidly, US study data show.

Doctor with x-ray of spine and patient

30-07-2020 | Osteoporosis | Highlight | News

Delayed denosumab dosing could raise vertebral fracture risk in patients with osteoporosis

Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

Doctor holding plastic heart in hands

24-06-2020 | Osteoporosis | Highlight | News

​​​​​​​Cardiovascular safety of romosozumab warrants ‘rigorous assessment’

Romosozumab and other sclerostin inhibitors may increase cardiovascular risk, suggests evidence from a meta-analysis of randomized trials and a study of genetic variants that mimic pharmacologic inhibition of sclerostin.